Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Chemical engineer Robert Langer wins QEPrize
http://www.tcetoday.com/latest%20news/2015/february/chemical-engineer-robert-langer-wins-qeprize.aspx#.VNHKo4Y76rU
Thanks investaholic, those with apple products can do the same.
Maybe the phrase that applies here is dog that barks doesn't bite... And since Ocata isn't barking, they're about to take a bite out of the mms and shorts!
http://www.bioheartinc.com/assets/press/BioheartUpdatesandDiversifiesItsClinicalDevelopmentPipeline.pdf
Bioheart Updates and Diversifies Its Clinical Development Pipeline ________________________________________________________________________ Sunrise, FL – January 29, 2015 – Bioheart, Inc., a Florida Corporation (BHRT.OB), an emerging enterprise in the regenerative medicine / cellular therapy industry announced today an update and diversification plan for its clinical development pipeline. The company’s update includes a realignment of its cardiovascular product candidates and diversification into the treatment of autoimmune diseases with a first generation, investigational research program to treat Rheumatoid Arthritis (RA).
Thanks for posting GS. It's a great read.
http://m.medicalxpress.com/news/2015-01-spain-stem-cell-therapy-hearts.html
BioHearts goals will be achieved imo
Cardiovascular Product Candidates
Bioheart will advance its MyocellTM and MyocellTM SDF-1 programs forward for the
treatment of chronic heart failure. The MyocellTM product candidate (known as the MARVEL clinical trial) will advance into US FDA phase 3 clinical evaluation for the treatment of chronic heart failure. The re-start of the MyocellTM clinical trial is conditional to re-engagement with the principle investigators and related institutional requirements and internal preparations. Additional information on the timing of patient enrollment will be given at a future date. The Company estimates that MyocellTM for the treatment of chronic heart failure could achieve market approval in 2019
http://www.bioheartinc.com/assets/press/BioheartUpdatesandDiversifiesItsClinicalDevelopmentPipeline.pdf
https://clinicaltrials.gov/ct2/show/NCT00526253?term=Bioheart&rank=1
In my opinion. Next weeks call will solidify the positive direction our company is headed in as well as update us even more on our phase 3.
http://www.bioheartinc.com/assets/press/BioheartConfirmsDateandAccessforShareholderConferenceCall.pdf
Again...ITS NOT THE TABLE, ITS THE MATERIAL. IMO THAT TABLE DIDNT TAKE 5 MINUTES TO MAKE... IT TOOK YEARS AND LOTS OF R&D AS WELL AS SPENDING IN ORDER TO PUT TOGETHER THE MATERIAL IN THE BOXES THAT MAKE UP THAT TABLE.
OR MAYBE ITS THE ACTUAL MATERIAL IN THE PRs!!??
Yeah what really impressed me was that all four of the candidates' status indicate that were on the move. So by the chart alone I anticipate a number of PRs in the future that will entail the pipeline progress. Also, the dates are very exciting considering how close we are to them IMO. All that plus revenues and partnerships, increasing... It's time for the PPS to begin showing our true value.
Yes sir! I checked it this morning and noticed as well!
I call it the killer instinct... and I like it.
Can you respond to post 12942?
Do you think there is ANYTHING POSITIVE about this company?
This is great news!!
Bioheart Confirms Date and Access for Shareholder Conference Call
Strategic Direction for 2015 and Forward to be Highlighted
________________________________________________________________________ Sunrise, FL – January 28, 2015 – Bioheart, Inc., a Florida Corporation (BHRT.OB),
http://www.bioheartinc.com/assets/press/BioheartConfirmsDateandAccessforShareholderConferenceCall.pdf
Forget the expenses. Revenues by definition are profits after expenses. And BHRT reports REVENUES!!
What is best for this stock?
No revenues with BHRTs expenses?
Or increasing revenues at exponential rates with BHRTs expenses?
Thanks for the reply investaholic, our thoughts pertaining to the investor conference are aligned. News pertaining to one of our phase 3s would be absolutely monumental. Either way, I believe the biggest picture here is that we are now generating revenues at an exponential rate. I expect the 10K will release at the same time as the conference call takes place. IMO
One way to look at it... Or the other, if they didn't believe in it... It could be lower?
Last week before the week of the conference call. Anyone have any thoughts on what we can expect on that call?
http://www.bioheartinc.com/assets/press/BioheartAnnouncesDateforShareholderConferenceCall.pdf
Imo yes indeed... And soon.
Bioheart, Inc. Files SEC Form SC 13G, Statement of Acquisition of Beneficial Ownership By Individuals
http://m.insurancenewsnet.com/oarticle/2015/01/23/bioheart-inc-files-sec-form-sc-13g-statement-of-acquisition-of-beneficial-own-a-586819.html
Does anyone have any idea what the average length of an SPO is or how long it can last, at a maximum?
Thanks for posting GS
Yes exactly. And the 10K is expected to have yet even more substantial increases in revenue.
Big Pharma.
You're wrong.
IMO definitely over 2 million in revenue for 2014 to be reported in the next 10K. PS that's an educated assumption based on "BioHeart trend"... Not personal hope.
Good read about R. Lanza
http://www.ft.com/cms/s/2/f8b4b95c-9a48-11e4-8426-00144feabdc0.html#slide0
8-K released for stock repurchase
http://ih.advfn.com/p.php?pid=nmona&article=65135322&xref=newsalert
On January 13, 2015, the Company issued a press release announcing that its board of directors has approved a share repurchase program authorizing the Company to repurchase outstanding common stock when beneficially prudent for the Company and its shareholders. A copy of the Company’s press release is attached hereto as Exhibit 99.1.
BIOHEART RELEASES Q2 FINANCIAL INFORMATION SHOWING GROWTH ________________________________________________________________________
Sunrise, Fla – August 7, 2014 – Bioheart, Inc. (BHRT.OB) released today financial information based on results from Q2 2014. The financial data shows that Bioheart has grown in product revenues, increased income, reduced debt, and further strengthened the financial standing of the company.
Bioheart product revenues are up from $24,321 to $819,606 comparing YTD 2013 to YTD 2014. The revenues recognized to date are related to sales of MyoCath, patient treatments, AdipoCell systems and related supplies, and cell culturing and banking services. Bioheart’s YTD net income increased to $226,034, as compared to a net loss of $1,269,231 in YTD 2013, primarily resulting from gain on settlement of debt.
“The financial backbone of Bioheart is getting stronger and we continue to make strides on a daily basis,” said Mike Tomas, Bioheart's president and CEO. “We have experienced two very strong quarters this year and will try to continue to improve
the well-being of Bioheart for our shareholders.”
Bioheart has continued to take steps to streamline operational costs, decreasing its net cash used in operating activities by 54% from $1,095,000 in YTD 2013 down to $507,000 in YTD 2014. Bioheart has been focused on reducing debt and decreasing current liabilities by $3.6 million (27%) from the beginning of the year. In addition, Bioheart has made strides to improve its working capital deficiency, decreasing the deficit by 28% from the beginning of the year.
The Financial Accounting Standards Board (FASB) issued an Accounting Standards Update (ASU) that restructures financial reporting for development stage entities by eliminating development stage reporting. Bioheart, as well as all entities in a development stage, will no longer need to present inception-to-date statements of operations or cash flows.
http://www.bioheartinc.com/assets/press/BIOHEARTRELEASESQ2FINANCIALINFORMATIONSHOWINGGROWTH.pdf
Here's the other side of the coin.
http://www.bioheartinc.com/News-Events/NewsReleases/2015/Q1
1/14/2015
Bioheart Announces Date for Shareholder Conference Call
1/13/2015
Bioheart Board of Directors Authorizes a Repurchase of the Company’s Outstanding Common Stock
12/22/2014
BIOHEART ANNOUNCES COMPLETION OF FIRST STEM CELL TRAINING IN AUSTRALIA
12/18/2014
BIOHEART ANNOUNCES JOINT VENTURE IN NIGERIA
11/17/2014
BIOHEART ANNOUNCES EXPANSION OF CLINICAL STUDY FOR DEGENERATIVE DISC DISEASE
11/12/2014
BIOHEART ANNOUNCES FIRST INTRACORONARY IMPLANTATION OF ADIPOSE STEM CELLS IN AZERBAIJAN
10/30/2014
Miami Dade College Names Bioheart CEO, Mike Tomas, to Board of Advisors for New Idea Center
10/24/2014
Bioheart, Inc Completes Financing with Magna
10/15/2014
Bioheart Announces Partnership in Colombia
10/13/2014
Bioheart Announces Positive 12 Month Preliminary Data from Phase I Angel Trial
9/24/2014
BIOHEART ANNOUNCES SUCCESSFUL GRAND OPENING OF FACILITY IN SOUTH AFRICA
9/16/2014
BIOHEART ANNOUNCES GRAND OPENING OF FACILITY IN SOUTH AFRICA
8/7/2014
BIOHEART RELEASES Q2 FINANCIAL INFORMATION SHOWING GROWTH
7/24/2014
BIOHEART ANNOUNCES WORLD’S FIRST COMBINATION STEM CELL TREATMENT
7/16/2014
BIOHEART ANNOUNCES GRAND OPENING OF MAGNUM CELL THERAPIES
7/7/2014
BIOHEART ANNOUNCES CLINICAL TRIALS IN INDIA
6/24/2014
BIOHEART ANNOUNCES JOINT VENTURE IN SOUTH AFRICA
6/4/2014
BIOHEART TO PRESENT AT THE PRP AND REGENERATIVE MEDICINE SYMPOSIUM
5/16/2014
BIOHEART TO PRESENT AT THE WORLD STEM CELLS & REGENERATIVE MEDICINE CONGRESS
5/15/2014
BIOHEART, INC. REPORTS SIGNIFICANT REVENUE INCREASES
5/13/2014
BIOHEART TO PRESENT AT 22ND MEDITERRANEAN CONFERENCE OF MEDICINE AND THERAPEUTIC COSMETIC SURGERY
5/5/2014
BIOHEART, INC. ANNOUNCES UPDATE ON PHASE I ADIPOSE STEM CELL TRIAL
4/30/2014
BIOHEART, INC. PRESENTED CLINICAL TRIAL RESULTS AT THE AGE MANAGEMENT MEDICINE GROUP CONFERENCE
4/23/2014
BIOHEART ANNOUNCES CLINICAL STUDY FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE
4/22/2014
BIOHEART, INC. TO PRESENT CLINICAL TRIAL RESULTS AT THE AGE MANAGEMENT MEDICINE GROUP CONFERENCE
4/2/2014
BIOHEART TO PRESENT AT SELECTBIO CLINICAL TRANSLATION OF STEM CELLS
I added to my position today. Regardless of the MMs. IMO it's dirt cheap at these levels
Imo the business is growing at the same rate they're moving. Excellent news.